GPRC5D positive
An alternative myeloma-cell target for heavily treated disease.
Parent marker: GPRC5D
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
GPRC5D is used as a target in several bispecific antibody and cellular therapy studies in advanced multiple myeloma.
How this finding appears in a report
Assessment is generally performed on the bone marrow; Examination availability varies between facilities.
When therapy stops working
Decreased target expression may occur following therapy targeting GPRC5D.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: GPRC5D
GPRC5D expression has been the basis for consideration of some bispecific antibody and cellular therapy studies in advanced multiple myeloma.
A negative result does not always mean absent
Summary
- Gen
- GPRC5D
- Variant
- GPRC5D expression positive
- Alteration type
- Immunophenotype
- Discussed in
- Multiple Myeloma
- Updated
- 2026-09-10
Other names in reports
GPRC5D+
Drugs discussed
Treatment categories
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- GPRC5D
Biomarker
Reason: Related through a biomarker
- Multiple Myeloma
Cancer type
Reason: Related to this page
- Talquetamab
Drug
Reason: Related to this page
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Related to this page
- Immunotherapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.